doi: 10.1523/JNEUROSCI.1865-19.2020 85 CarboneFVerschuerenSRotondoATackJ
doi: 10.1530/JOE-17-0278 66 TufailESanyalSMithalASanyalSChattopadhyayN
In my private practice, I started using GLP-1 drugs such as exenatide in 2006 and liraglutide in 2010 for my patients with type 2 diabetes
hard boiled egg on the side for more protein Smashed avocado and white beans on whole wheat toast Lunch Black bean soup, carrots and hummus Chicken and brown rice bowl with salsa Turkey sandwich on whole wheat bread, carrot sticks, pear Dinner Salmon, baked sweet potato, roasted Brussels sprouts Cabbage and beef skillet, seasoned with rice vinegar and low-sodium soy sauce and served over barley Tofu and pea stir fry Final Considerations Timing of meals and other eating habits may also influence GLP-1 levels
Non-genetic predictors of BMI loss To analyse the dependence of achieved BMI loss on non-genetic factors such as drug type, dosage and time on treatment, we fit the following model: where drugType is an indicator variable that equals 1 for individuals using semaglutide and 0 for tirzepatide, dose represents the dose in milligrams, days treat represents the total days on the relevant drug and : represents an interaction term between two or more variables
